Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low initial-dose versus national protocol opium tincture for opioid withdrawal induction
IRCT20260927071204N1Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of opium tincture in opioid use disorder (OUD) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Opium tincture dosage required for symptom control. Started Oct 2026; status: recruiting.
02
Drugs
opium tincture
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on IRCT20260927071204N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260927071204N1.